A cost analysis of medications prescribed by vascular surgeons
Journal of Vascular Surgery · 2025
DOI: 10.1016/j.jvs.2024.08.022 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Vascular Surgery, 2025. Verfasst von Shourya Verma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Michigan State University College of Human Medicine, East Lansing, MI. Hauptthemen laut MEDLINE: Drug Costs, Cost-Benefit Analysis, Vascular Surgical Procedures, Cost Savings. Die Arbeit nennt 3 Literaturangaben. Gefördert von: Michigan State University.
Abstract (Originalsprache)
OBJECTIVE: Various pharmaceutical cost options have been developed by multiple companies such as GoodRx, Amazon Pharmacy, Mark Cuban Cost Plus Drugs (CPD), Health Warehouse, and local retail pharmacies) to curb the cost of prescription medications prices that patients are having to bear. Vascular surgeons provide long-term continuity of care to patients with vascular disease who often require long-term medical management. This study sought to compare the different pharmaceutical options available for the most prescribed medications by vascular surgeons to their patients and to understand which of them are the most cost-effective. METHODS: The Medicare Part D catalog and vascular surgical literature were evaluated to identify which medications are most prescribed by vascular surgeons. The average price per tablet being paid by patients was identified using the Agency for Healthcare and Research database. The prices per tablet for each of the above pharmaceutical companies were found using online catalogs or coupons. The prices were then compared using analysis of variance and t-tests. RESULTS: All four pharmaceutical cost options provide medication cost savings to patients compared with retail pharmacy costs. Analysis of variance showed that there were statistically significant differences among the different pharmaceutical cost options (F 15.44>2.36; P < .001). Mark Cuban CPD provided the most significant cost advantage over the other pharmaceutical options (P < .01). On a national scale, medications prescribed by vascular surgeons through Mark Cuban CPD could provide a 52% cost reduction to patients with vascular disease with a potential annual savings of over $3 billion dollars for the selected medications. CONCLUSIONS: CPD shows a strong potential for cost savings for patients commonly prescribed medications by vascular surgeons. As a specialty that provides long-term care and establishes long-term relationships with its patients, vascular surgeons have the unique ability to impact their overall health in a meaningful way by limiting the financial burdens associated with vascular-based medication acquisition and utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Michigan State University College of Human Medicine, East Lansing, MI.
- Division of Vascular Surgery, Department of Surgery, Michigan State University College of Human Medicine, East Lansing, MI.
- Michigan State University College of Human Medicine, East Lansing, MI; Division of Vascular Surgery, Department of Surgery, Michigan State University College of Human Medicine, East Lansing, MI. Electronic address: linj…
Förderung
- Michigan State University
Zitieren
APA
Verma, S., Wood, H. R., Chen, H., Knepper, J. K., & Lin, J. C. (2025). A cost analysis of medications prescribed by vascular surgeons. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2024.08.022
Vancouver
Verma S, Wood HR, Chen H, Knepper JK, Lin JC. A cost analysis of medications prescribed by vascular surgeons. Journal of Vascular Surgery. 2025. doi:10.1016/j.jvs.2024.08.022
BibTeX
@article{Verma2025,
author = {Verma, Shourya and Wood, Hayden R and Chen, Huiting and Knepper, Jordan K and Lin, Judith C},
title = {A cost analysis of medications prescribed by vascular surgeons},
journal = {Journal of Vascular Surgery},
year = {2025},
doi = {10.1016/j.jvs.2024.08.022}
}
EUVIMED